Prescient Therapeutics Information

View Top Employees from Prescient Therapeutics

Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Prescient’s technologies emanate from prestigious world class centres including Yale, Penn, Oxford and Moffitt. Targeted therapy: Prescient’s first in class targeted therapy – PTX-100 – is currently in clinical development and showing encouraging activity in diseases of unmet need. Cell therapies: Prescient owns the exclusive rights to two next-generation cell therapy platform technologies, OmniCAR and CellPryme – both with the potential to enhance CAR-T therapies and overcome challenges faced by current generation approaches

Website	http://www.ptxtherapeutics.com
Employees	12 (7 on RocketReach)
Founded	2014
Address	Level 11, 385 Bourke Street, Suite 2, Melbourne, Victoria 3205, AU
Industry	Biotechnology Research, Biotechnology, Drug Discovery
Web Rank	23 Million
Keywords	Oncology Therapeutics, Cancer Treatment, Personalized Medicine, Targeted Therapies, Cellular Therapies, Clinical Stage Oncology, Cancer Research, Drug Development, Biotechnology, Pharmaceutical, Immunotherapy, Precision Medicine, Cancer Immunotherapy, Oncology Research, Clinical Trials, Therapeutic Development, Molecular Medicine, Drug Discovery, Biopharma
Competitors	Amgen, Gilead Sciences, Bristol Myers Squibb, Genentech, Novartis, Roche, Pfizer, Lilly India, AstraZeneca, Merck & Co., Inc. +68 more (view full list)